menu
    • menu
    [{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"||VE-PTP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"||VE-PTP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"VE-PTP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"VE-PTP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Inapplicable"}]

    Find Ophthalmology Clinical Drug Pipeline Developments & Deals by Aerpio Pharmaceuticals

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Razuprotafib,Prostaglandin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort

                            Details : The Phase 1b trial is a randomized, double-masked study designed to assess increasing concentrations of AKB-9778 dosed topically as eye drops.

                            Product Name : AKB-9778

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 02, 2020

                            Lead Product(s) : Razuprotafib,Prostaglandin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial

                            Details : The study is designed to evaluate the safety and efficacy of a topical ocular formulation of razuprotafib in approximately 195 patients followed over a 28-day period, and patients must undergo a 28-day washout prior to randomization.

                            Product Name : AKB-9778

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 15, 2020

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Razuprotafib,Prostaglandin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Topical Ocular Formulation of Aerpio Pharmaceutical’s AKB-9778 Product Candidate Produced IOP Lowering with ...

                            Details : Topical ocular administration of AKB-9778 was well tolerated over seven days in cohort 5.

                            Product Name : AKB-9778

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 01, 2020

                            Lead Product(s) : Razuprotafib,Prostaglandin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial

                            Details : Aerpio Pharmaceuticals has commenced patient enrollment in its double-blind, placebo-controlled Phase 2 trial in patients with elevated intraocular pressure (IOP) associated with open angle glaucoma (OAG) or ocular hypertension (OHT).

                            Product Name : AKB-9778

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 24, 2020

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth